The Fuchs Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Fuchs Dystrophy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Fuchs Dystrophy Market.
Some of the key takeaways from the Fuchs Dystrophy Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Fuchs Dystrophy treatment therapies with a considerable amount of success over the years.
-
Fuchs Dystrophy companies working in the treatment market are Design Therapeutics, Emmecell, Santen Inc., Trefoil Therapeutics, Kowa Company, Ltd, Adam Fedyk, MD, FACS, Kowa Research Institute, Inc., Santen Inc., and others, are developing therapies for the Fuchs Dystrophy treatment
-
Emerging Fuchs Dystrophy therapies in the different phases of clinical trials are- DT-168, EO2002, STN1010904, TTHX 1114, Ripasudil, BSS Plus, Ripasudil, STN1010904, and others are expected to have a significant impact on the Fuchs Dystrophy market in the coming years.
-
In April 2023, Trefoil Therapeutics has released further results from the Phase II STORM trial of TTHX1114, aimed at protecting endothelial cells from damage caused by cataract surgery in Fuchs endothelial corneal dystrophy (FECD) patients undergoing Descemet Stripping Only (DSO). The findings indicated that TTHX1114 triggered a dose-dependent improvement in corneal edema resolution and enhanced best corrected visual acuity (BCVA) post-surgery in all patients.
-
In March 2023, Kowa Company Ltd has begun a Phase III study to assess the safety and efficacy of Ripasudil (K-321) eye drops in subjects with Fuchs endothelial corneal dystrophy after descemetorhexis. The trial is double-masked, randomized, and placebo-controlled, featuring a 12-week administration period with a two-week gradual dose taper phase and a 38-week follow-up phase.
Fuchs Dystrophy Overview
Fuchs endothelial corneal dystrophy (FECD) is a progressive eye disease that affects the cornea, the clear, dome-shaped surface that covers the front of the eye. It specifically involves the endothelial layer of the cornea, which is responsible for maintaining corneal clarity by pumping out excess fluid. In Fuchs dystrophy, the endothelial cells gradually deteriorate and die off, leading to fluid buildup (edema) in the cornea.
Get a Free Sample PDF Report to know more about Fuchs Dystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/fuchs-dystrophy-pipeline-insight
Emerging Fuchs Dystrophy Drugs Under Different Phases of Clinical Development Include:
-
DT-168: Design Therapeutics
-
EO2002: Emmecell
-
STN1010904: Santen Inc.
-
TTHX 1114: Trefoil Therapeutics
-
Ripasudil: Kowa Company, Ltd
-
BSS Plus: Adam Fedyk, MD, FACS
-
Ripasudil: Kowa Research Institute, Inc.
-
STN1010904: Santen Inc.
Fuchs Dystrophy Route of Administration
Fuchs Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Fuchs Dystrophy Molecule Type
Fuchs Dystrophy Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Fuchs Dystrophy Pipeline Therapeutics Assessment
-
Fuchs Dystrophy Assessment by Product Type
-
Fuchs Dystrophy By Stage and Product Type
-
Fuchs Dystrophy Assessment by Route of Administration
-
Fuchs Dystrophy By Stage and Route of Administration
-
Fuchs Dystrophy Assessment by Molecule Type
-
Fuchs Dystrophy by Stage and Molecule Type
DelveInsight’s Fuchs Dystrophy Report covers around 5+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Fuchs Dystrophy product details are provided in the report. Download the Fuchs Dystrophy pipeline report to learn more about the emerging Fuchs Dystrophy therapies
Some of the key companies in the Fuchs Dystrophy Therapeutics Market include:
Key companies developing therapies for Fuchs Dystrophy are – AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc., Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, Presbia Plc, and others.
Fuchs Dystrophy Pipeline Analysis:
The Fuchs Dystrophy pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Fuchs Dystrophy with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fuchs Dystrophy Treatment.
-
Fuchs Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Fuchs Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fuchs Dystrophy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Fuchs Dystrophy drugs and therapies
Fuchs Dystrophy Pipeline Market Strengths
-
Increase in the geriatric population, growing demand for eye care treatment for Fuchs dystrophy are some of the important factors that are fueling the Fuchs Dystrophy Market.
Fuchs Dystrophy Pipeline Market Opportunities
-
However, lack of awareness, lack of universal guidelines regarding disease diagnosis and treatment impacts the treatment regime for the patient and other factors are creating obstacles in the Fuchs Dystrophy Market growth.
Scope of Fuchs Dystrophy Pipeline Drug Insight
-
Coverage: Global
-
Key Fuchs Dystrophy Companies: Design Therapeutics, Emmecell, Santen Inc., Trefoil Therapeutics, Kowa Company, Ltd, Adam Fedyk, MD, FACS, Kowa Research Institute, Inc., Santen Inc., and others
-
Key Fuchs Dystrophy Therapies: DT-168, EO2002, STN1010904, TTHX 1114, Ripasudil, BSS Plus, Ripasudil, STN1010904, and others
-
Fuchs Dystrophy Therapeutic Assessment: Fuchs Dystrophy current marketed and Fuchs Dystrophy emerging therapies
-
Fuchs Dystrophy Market Dynamics: Fuchs Dystrophy market drivers and Fuchs Dystrophy market barriers
Request for Sample PDF Report for Fuchs Dystrophy Pipeline Assessment and clinical trials
Table of Contents
1. Fuchs Dystrophy Report Introduction
2. Fuchs Dystrophy Executive Summary
3. Fuchs Dystrophy Overview
4. Fuchs Dystrophy- Analytical Perspective In-depth Commercial Assessment
5. Fuchs Dystrophy Pipeline Therapeutics
6. Fuchs Dystrophy Late Stage Products (Phase II/III)
7. Fuchs Dystrophy Mid Stage Products (Phase II)
8. Fuchs Dystrophy Early Stage Products (Phase I)
9. Fuchs Dystrophy Preclinical Stage Products
10. Fuchs Dystrophy Therapeutics Assessment
11. Fuchs Dystrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Fuchs Dystrophy Key Companies
14. Fuchs Dystrophy Key Products
15. Fuchs Dystrophy Unmet Needs
16 . Fuchs Dystrophy Market Drivers and Barriers
17. Fuchs Dystrophy Future Perspectives and Conclusion
18. Fuchs Dystrophy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Guarav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/